Roadman Investments’ (LITT.V) recent acquisition target CLOV Biopharma (CBP) is continuing its research into the potential commercial uses of cedar leaf oil vapour (CLOV), specifically when it comes to the health care and biotechnology, and believes it may help fight the COVID-19 coronavirus.
Soligenix (SNGX.Q), a biopharma company that develops and commercializes products for rare diseases, announced that its RiVax, which is a heat stable ricin toxin vaccine, has received a fast track designation from the US Food and Drug Administration (FDA).
If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there. For the high risk, high reward investor, nothing is quite like the thrill of correctly picking when a long, drawn out, US Food and Drug Administration process of approving a new drug finally gets over the line.
Xphyto (XPHY.C) is dominating the cannabis sector like Sean Kemp used to dominate the Seattle buffet scene. It’s a legit beast right now, jumping from fat new high to fat new high. We’ve sat with their team several times over the past year and on each occasion have been impressed with their plans, but perhaps the greatest plan they’ve executed has been achieved over the past month, when their share price has elevated from $1.00 to $1.85.
The first time we dealt with a coronavirus I was a lonely college student in Oshawa, Ontario and folks around me thought briefly that the world was coming to an end.
Eli Lilly and company (LLY.NYSE) and robotic cloud-computing provider, Strateos, unveiled the Lilly Life Sciences Studio lab, a new robotic laboratory in San Diego, Calfornia, designed to accelerate the drug discovery process today.
Amgen (AMGN.Q) signed a lease with BioMed Realty for a new 240,000 square foot Leadership in Energy and Environmental Design (LEED) candidate facility in the Gateway of Pacific campus development in south San Francisco earlier this week.
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth a combined $5.2 billion.
When markets closed Friday November 15, Karuna Therapeutics (KRTX.Q) was just another pharma-stock trading in the mid-teens trying to make drugs for patients with Alzheimer’s and Schizophrenia.
Johnson & Johnson (JNJ.NYSE) issued a recall for a single lot of its Baby Powder in response to a FDA test that uncovered the presence of sub-trace levels (no greater than 0.00002%) of chrysotile asbestos contamination in samples from a single bottle purchased from an online retailer.
My best friend growing up married a woman with severe rhinosinusitis and nasal polyps. That sounds about as serious as a case of the common cold and a bad headache, but there were many lost nights where my friend and his wife required an ER visit to get her breathing again.
Cannabis has been good to us here at equity.guru. There are 1,283 pages of cannabis-related content on our site and it’s still growing.